Cleveland Biolabs receives DOD funding recommendation
In animal models, the compound showed efficacy in treating and preventing fatality following high doses of radiation, similar to what would be released in an attack or accident. Animals that received the entolimod showed survival rates of approximately 75 percent as opposed to 27.5 percent in untreated animals.
Entolimod also has fared well in human trials, producing biomarkers indicative of its efficiency. It has been administered to 245 individuals who are in the late stages of cancer.
"We are grateful for the continued support of the Department of Defense for entolimod's development as a broad spectrum medical radiation countermeasure," Cleveland Biolabs CEO Yakov Kogan said. "We believe entolimod offers a viable solution to protect our military personnel and civilians from the potentially deleterious effects of ionizing radiation, and hope to contribute to our nation's preparedness."
Based on the study results, the company can submit the radiation countermeasure candidate for pre-Emergency Use Authorization from the U.S. Food and Drug Administration.
The company and the DOD's Office of Congressionally Directed Medical Research Programs now must negotiate further research and development of entolimod.